Recursion Pharmaceuticals, Inc. Class A Common Stock RXRX

$3.16 -4.53% at last close

Recent SEC Filings

FormDescriptionFiledDocument
4 FORM 4 2026-08-06 View →
10-Q 10-Q 2026-08-05 View →
8-K 8-K 2026-08-05 View →
4 FORM 4 2026-07-09 View →
4 FORM 4 2026-07-02 View →
4 FORM 4 2026-07-02 View →
4 FORM 4 2026-06-22 View →
4 FORM 4 2026-06-22 View →
4 FORM 4 2026-06-22 View →
4 FORM 4 2026-06-22 View →
4 FORM 4 2026-06-22 View →
4 FORM 4 2026-06-22 View →
4 FORM 4 2026-06-22 View →
8-K 8-K 2026-06-18 View →
4 FORM 4 2026-06-17 View →
4 FORM 4 2026-06-05 View →
4 FORM 4 2026-06-05 View →
4 FORM 4 2026-06-04 View →
4 FORM 4 2026-06-04 View →
4 FORM 4 2026-05-27 View →
4 FORM 4 2026-05-19 View →
4 FORM 4 2026-05-19 View →
4 FORM 4 2026-05-19 View →
4 FORM 4 2026-05-19 View →
4 FORM 4 2026-05-08 View →
4 FORM 4 2026-05-07 View →
10-Q 10-Q 2026-05-06 View →
8-K 8-K 2026-05-06 View →
DEF 14A DEF 14A 2026-04-30 View →
8-K 8-K 2026-04-30 View →
4 FORM 4 2026-04-24 View →
4 FORM 4 2026-04-08 View →
4 FORM 4 2026-04-08 View →
4 FORM 4 2026-04-08 View →
4 FORM 4 2026-04-02 View →
4 FORM 4 2026-04-02 View →
8-K 8-K 2026-03-25 View →
4 FORM 4 2026-03-25 View →
4 FORM 4 2026-03-18 View →
4 FORM 4 2026-03-11 View →

Filings are sourced directly from the SEC's EDGAR system. Annual reports (10-K) and quarterly reports (10-Q) carry the full financial statements; 8-K filings disclose material events between reports; Form 4 filings record insider purchases and sales.

Key Stats

Last Close
$3.16
Market Cap
$1.76 billion
52-Week Range
$2.77 $7.18
Average Volume
19.05 million shs

Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.